Cargando…

A dietary intervention study to reduce Metabolic Syndrome risks in heart-transplanted patients

BACKGROUND: Since heart transplantation (HTx) has become the gold standard therapy in end-staged heart failure, many factors, including metabolic syndrome (MS), represent a burden in HTx patients. Considering key role of immunosuppressive therapy and its side effects on the appearance of MS, we focu...

Descripción completa

Detalles Bibliográficos
Autores principales: Valdi, G, Ferrara, V, Marinoni, M, Nalli, C, Di Nora, C, Sponga, S, Benedetti, G, Parpinel, M, Livi, U, Moretti, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834904/
http://dx.doi.org/10.1093/eurpub/ckac131.240
_version_ 1784868566485434368
author Valdi, G
Ferrara, V
Marinoni, M
Nalli, C
Di Nora, C
Sponga, S
Benedetti, G
Parpinel, M
Livi, U
Moretti, V
author_facet Valdi, G
Ferrara, V
Marinoni, M
Nalli, C
Di Nora, C
Sponga, S
Benedetti, G
Parpinel, M
Livi, U
Moretti, V
author_sort Valdi, G
collection PubMed
description BACKGROUND: Since heart transplantation (HTx) has become the gold standard therapy in end-staged heart failure, many factors, including metabolic syndrome (MS), represent a burden in HTx patients. Considering key role of immunosuppressive therapy and its side effects on the appearance of MS, we focused on modifiable factors including adherence to Mediterranean Diet (MD) and improvement of dietary habits. METHODS: 21 heart-transplanted patients were enrolled and randomized in a control group (CG; N 10) and an intervention group (IG; N 11). During two meetings (baseline, 6-month follow-up) were administered a validated Food Frequency Questionnaire (FFQ), to assess adherence to MD, and collected clinical and anthropometric parameters, IG were additionally requested to fill a food diary. IG received personalized advices, CG received standard recommendations. Comparison between IG and CG were analyzed, differences into the IG were also assessed. RESULTS: The prevalence of MS at baseline was 46% in IG and 20% in CG. During 6-month follow-up, significant lower blood pressure values were observed (median, 25th-75th: systolic 130, 120-130 IG vs 145, 130-147 CG; p = 0.004). Seven patients of IG underwent a 12-month meeting. In this group MD scores increased significantly (7 + 1.3 vs 4 + 1.5, p = 0.001). Furthermore, significant decrease of fat mass percentage (%) (23.3 + 6.3 vs 14.8 + 10.1, p = 0.014), increase of fat free mass % (76 + 6.3 vs 85.2 + 10.1, p = 0.014) and increase of body cell mass % (50.9 + 3.8 vs 53.4 + 3.4, p = 0.031) were observed. Dietary data in IG showed significant decrease of energy from saturated fatty acids % (13.0±2.1 vs 9.6±1.5, p = 0.001), sodium (mg) (2138±359 vs 1822±417, p = 0.045), and decreasing trend for cholesterol (mg) (219±82 vs 171±59, p = 0.082). CONCLUSIONS: Dietary intervention based on MD perhaps can improve MS risks in heart-transplanted patients. Further investigations may be needed to assess the fundamental role of a structured nutritional follow-up in these patients. KEY MESSAGES: • Personalized nutritional advices based on the MD, compared to general recommendation, can significantly improve health and quality of life in heart-transplanted patients. • A structured nutritional follow-up for heart-transplanted patients may be desirable to prevent risks of Metabolic Syndrome as a public health instrument in selected categories as these patients.
format Online
Article
Text
id pubmed-9834904
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98349042023-01-12 A dietary intervention study to reduce Metabolic Syndrome risks in heart-transplanted patients Valdi, G Ferrara, V Marinoni, M Nalli, C Di Nora, C Sponga, S Benedetti, G Parpinel, M Livi, U Moretti, V Eur J Public Health Poster Displays BACKGROUND: Since heart transplantation (HTx) has become the gold standard therapy in end-staged heart failure, many factors, including metabolic syndrome (MS), represent a burden in HTx patients. Considering key role of immunosuppressive therapy and its side effects on the appearance of MS, we focused on modifiable factors including adherence to Mediterranean Diet (MD) and improvement of dietary habits. METHODS: 21 heart-transplanted patients were enrolled and randomized in a control group (CG; N 10) and an intervention group (IG; N 11). During two meetings (baseline, 6-month follow-up) were administered a validated Food Frequency Questionnaire (FFQ), to assess adherence to MD, and collected clinical and anthropometric parameters, IG were additionally requested to fill a food diary. IG received personalized advices, CG received standard recommendations. Comparison between IG and CG were analyzed, differences into the IG were also assessed. RESULTS: The prevalence of MS at baseline was 46% in IG and 20% in CG. During 6-month follow-up, significant lower blood pressure values were observed (median, 25th-75th: systolic 130, 120-130 IG vs 145, 130-147 CG; p = 0.004). Seven patients of IG underwent a 12-month meeting. In this group MD scores increased significantly (7 + 1.3 vs 4 + 1.5, p = 0.001). Furthermore, significant decrease of fat mass percentage (%) (23.3 + 6.3 vs 14.8 + 10.1, p = 0.014), increase of fat free mass % (76 + 6.3 vs 85.2 + 10.1, p = 0.014) and increase of body cell mass % (50.9 + 3.8 vs 53.4 + 3.4, p = 0.031) were observed. Dietary data in IG showed significant decrease of energy from saturated fatty acids % (13.0±2.1 vs 9.6±1.5, p = 0.001), sodium (mg) (2138±359 vs 1822±417, p = 0.045), and decreasing trend for cholesterol (mg) (219±82 vs 171±59, p = 0.082). CONCLUSIONS: Dietary intervention based on MD perhaps can improve MS risks in heart-transplanted patients. Further investigations may be needed to assess the fundamental role of a structured nutritional follow-up in these patients. KEY MESSAGES: • Personalized nutritional advices based on the MD, compared to general recommendation, can significantly improve health and quality of life in heart-transplanted patients. • A structured nutritional follow-up for heart-transplanted patients may be desirable to prevent risks of Metabolic Syndrome as a public health instrument in selected categories as these patients. Oxford University Press 2022-10-25 /pmc/articles/PMC9834904/ http://dx.doi.org/10.1093/eurpub/ckac131.240 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Displays
Valdi, G
Ferrara, V
Marinoni, M
Nalli, C
Di Nora, C
Sponga, S
Benedetti, G
Parpinel, M
Livi, U
Moretti, V
A dietary intervention study to reduce Metabolic Syndrome risks in heart-transplanted patients
title A dietary intervention study to reduce Metabolic Syndrome risks in heart-transplanted patients
title_full A dietary intervention study to reduce Metabolic Syndrome risks in heart-transplanted patients
title_fullStr A dietary intervention study to reduce Metabolic Syndrome risks in heart-transplanted patients
title_full_unstemmed A dietary intervention study to reduce Metabolic Syndrome risks in heart-transplanted patients
title_short A dietary intervention study to reduce Metabolic Syndrome risks in heart-transplanted patients
title_sort dietary intervention study to reduce metabolic syndrome risks in heart-transplanted patients
topic Poster Displays
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834904/
http://dx.doi.org/10.1093/eurpub/ckac131.240
work_keys_str_mv AT valdig adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT ferrarav adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT marinonim adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT nallic adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT dinorac adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT spongas adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT benedettig adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT parpinelm adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT liviu adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT morettiv adietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT valdig dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT ferrarav dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT marinonim dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT nallic dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT dinorac dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT spongas dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT benedettig dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT parpinelm dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT liviu dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients
AT morettiv dietaryinterventionstudytoreducemetabolicsyndromerisksinhearttransplantedpatients